Stephan Grupp Md Phd

This study is testing a new version of CAR T-cell therapy for children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to target cancer cells. The trial aims to …

This early-phase trial is testing a new treatment called CART123 for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. CART123 cells are specially engineered immune cells designed to find and kill leukemia cells. …

This study tests a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It combines two types of engineered immune cells (CAR T cells) that target different markers on cancer cells (CD19 and …

This phase 2 trial is testing a personalized cell therapy called CART19 in children and young adults with certain high-risk forms of B-cell acute lymphoblastic leukemia (B-ALL). The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack c…

This early-stage trial is testing a new treatment called GPC2 CAR T cells for children with neuroblastoma or retinoblastoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize a…

This early-phase study tests a new treatment called BEAM-201 for children and young adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments. BEAM-201 uses donor-derived immune cells that are engin…

This study tests whether a stem cell transplant using the patient's own cells can help young people (ages 8 to 25) with life-threatening lupus or scleroderma. The goal is to wipe out the faulty immune system and allow a new, healthy one to grow. The trial will track how long pati…